Study ID: ACCRU Nektar 11-PIR-11; BEACON
Description:

THE BEACON STUDY (BREAST CANCER OUTCOMES WITH NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician?s Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane,and Capecitabine

Location:
Sioux Falls Region,Fargo Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen MD
Disease:
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list